2023-505116-37-00RecruitingPhase 2
Exploratory evaluation of the effect of cholestyramine on serum levels of persistent organic pollutants in obese patients
Source: EU CTIS (euclinicaltrials.eu) · Last updated 27 Apr 2026
Brief summary (registry, in English)
To evaluate the effect of cholestyramine treatment on serum concentrations of different persistent organic pollutants in a population of obese women of childbearing age for whom bariatric surgery is indicated
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 14 Apr 2023
- Start date
- 8 Feb 2024
- Lead sponsor
- Centre Hospitalier Universitaire De Nice
- Diseases
- Obesity
- EU CT number
- 2023-505116-37-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 40
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with obesity who are planning bariatric surgery. It studies whether cholestyramine lowers pollutant levels in the blood.
- Age
- 18 to 45 years (the inclusion criteria); the record's age fields say 18 Years to 64 Years.
- Sex
- Women only.
- Disease stage
- Obesity with an accepted reason for bariatric surgery: BMI > 40 kg/m2, or BMI > 35 kg/m2 with complication(s) that surgery can improve.
- Earlier treatment
- Cannot be taking anti-vitamin K, digoxin or levothyroxine, or likely to take them within 3 months of joining.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Known allergy or intolerance to cholestyramine
- Chronic constipation
- Phenylketonuria
- Chronic disease that may affect the treatment, such as unbalanced diabetes with HbA1c >7%, known and treated dyslipidaemia, chronic renal failure with GFR <60 ml/min, or hepatocellular failure
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients on anti-vitamin K, digoxin, levothyroxine or likely to be on such therapy within 3 months of inclusion.
Other illness
- Known allergy or intolerance to cholestyramine
Lab values
- Chronic disease that may interfere with the efficacy of treatment (unbalanced diabetes with HbA1c >7%, known and treated dyslipidaemia, chronic renal failure with GFR <60 ml/min, hepatocellular failure)
Other
- Pregnant or breastfeeding women
- Chronic constipation
- Phenylketonuria
Who the study is looking for
- Female patients with an accepted indication for bariatric surgery (BMI > 40 kg/m2 or BMI > 35 kg/m2 with complication(s) improveable by surgery)
- Aged between 18 and 45 years
- Having effective contraception (according to Recommendations related to contraception and pregnancy testing in clinical trials Version 1.2 (CTCG Clinical Trials Coordination Group))
Age in the registry: 18 years to 64 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Universitaire de Nice | Nice | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.